

1 **DNA methylation profiling of immune cells from tuberculosis-exposed individuals**  
2 **overlaps with BCG-induced epigenetic changes and correlates with the emergence of anti-**  
3 **mycobacterial ‘corralling cells’**

4

5 Isabelle Pehrson<sup>1</sup>∂, Clara Braian<sup>1</sup>∂, Lovisa Karlsson<sup>1</sup>∂, Nina Idh<sup>1</sup>, Eva Kristin Danielsson<sup>1</sup>,  
6 Blanka Andersson<sup>1</sup>, Jakob Paues<sup>1,2</sup> Jyotirmoy Das<sup>1</sup>• and Maria Lerm<sup>1</sup>•\*

7

8

9 <sup>1</sup>Division of Infection and Inflammation, <sup>2</sup>Division of Infectious Diseases

10 Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences,  
11 Linköping University, SE-58185, Linköping, Sweden.

12

13

14

15 ∂) *Shared first authorship*

16 •) *Shared last authorship*

17 \*) *Corresponding author:*

18

19

20 Maria Lerm, Professor in Medical Microbiology, Div. of Inflammation and Infection, Lab 1,  
21 floor 12, Dept. of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences  
22 Linköping University, SE-58185 Linköping, Sweden, Phone: +46-732707786, E-mail:  
23 maria.lerm@liu.se

24

25

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## **Abstract**

The mechanism of protection of the only approved tuberculosis (TB) vaccine, Bacillus Calmette Guérin (BCG) is poorly understood. In recent years, epigenetic modifications induced by BCG have been demonstrated to reflect a state of trained immunity. The concept of trained immunity is now explored as a potential prevention strategy for a variety of infections. Studies on human TB immunity are dominated by those using peripheral blood as surrogate markers for immunity. Here, we instead studied the lung compartment by obtaining induced sputum from subjects included in a TB contact tracing. CD3- and HLA-DR-positive cells were isolated from the collected sputum and DNA methylome analyses performed. Unsupervised cluster analysis revealed that DNA methylomes of cells from TB-exposed individuals and controls appeared as separate clusters, and the numerous genes that were differentially methylated were functionally connected. The enriched pathways were strongly correlated to previously reported epigenetic changes and trained immunity in immune cells exposed to the BCG vaccine in human and animal studies. We further demonstrated that similar pathways were epigenetically modified in human macrophages trained with BCG *in vitro*. Finally, we found evidence of an *M. tuberculosis*-triggered emergence of a non-macrophage cell population from BCG-trained macrophage cultures. These cells did not phagocytose *M. tuberculosis*, but ‘corralled’ the bacteria into focal points, resulting in limitation of bacterial growth. Altogether, our study demonstrates that similar epigenetic changes are induced by *M. tuberculosis* and BCG and suggests that the modifications promote transformation of macrophages (or an unknown progenitor) to establish a yet undescribed cellular defense mechanism which we term ‘corralling’, based on the metaphorical resemblance to sheepdog herding.

## 50 **Introduction**

51 Tuberculosis (TB) is a pulmonary infection of pandemic rank and an expansion of the current  
52 toolkit for diagnosis, prevention and treatment is critical for reaching the United Nations'  
53 Sustainable Development Goals for 2030 of ending the TB epidemic<sup>1</sup>. TB is caused by  
54 *Mycobacterium tuberculosis*, which transmit via aerosols and target alveolar macrophages in  
55 exposed individuals<sup>2</sup>. In susceptible hosts, the bacteria replicate inside the macrophages and  
56 use them as trojan horses in order to disseminate in the tissues<sup>3</sup>. Bacillus Calmette Guérin, a  
57 non-virulent derivative of *Mycobacterium bovis*, has been used for almost a century as a vaccine  
58 against TB, with variable efficacy. Numerous studies have failed to provide correlates of  
59 protection, leaving the vaccine mechanism elusive. In recent years, the concept of trained  
60 immunity has evolved as an epigenetically encoded immune memory that can be triggered by  
61 a variety of stimuli and is reflected in a reprogrammed immune state characterized by a higher  
62 magnitude of response to subsequent pathogen challenges. The discovery of epigenetically  
63 regulated antimicrobial defense mechanisms goes beyond the classical understanding of  
64 immune defense and opens up a new field of research. Along this line, we have demonstrated  
65 that administration of the BCG vaccine to healthy subjects induced profound epigenetic  
66 alterations in immune cells, which correlated with enhanced anti-mycobacterial activity in  
67 macrophages isolated from the vaccinees<sup>4</sup>. The changes were reflected in the DNA methylome,  
68 with the strongest response being recorded within weeks after vaccination<sup>4</sup>. Our observation  
69 that BCG induces alterations of the DNA methylome of immune cells has later been confirmed  
70 by others<sup>5,6</sup>. Since BCG vaccination reflects an *in vivo* interaction between immune cells and  
71 viable mycobacteria, we here hypothesized that natural exposure to *M. tuberculosis* would  
72 induce similar changes not only in TB patients, but also in individuals who have been exposed  
73 to TB. Analyses of DNA methylomes of immune cells isolated from lungs and peripheral blood  
74 allowed us to identify distinct DNA methylation (DNAm) signatures in TB-exposed

75 individuals. Pathway analyses revealed strong overlaps with previous studies on BCG-induced  
76 epigenetic signatures that could be correlated with protection against *M. tuberculosis*. We  
77 therefore set up an experiment to scrutinize the anti-mycobacterial mechanisms correlating with  
78 BCG-induced epigenetic reprogramming in human primary macrophages. BCG-trained  
79 macrophages were subjected to DNA methylome analysis and in parallel monitored in a live  
80 cell imaging system during exposure to *M. tuberculosis*. Again, the DNAm change *in vitro*  
81 highly overlapped with the signatures of the TB-exposed individuals and the previously  
82 identified BCG-induced epigenetic changes. Guided by these findings, we designed  
83 experiments to monitor the events taking place in BCG-trained cells challenged with *M.*  
84 *tuberculosis*. To our surprise, rapidly dividing, non-phagocytic cells with a size of  
85 approximately 1/4<sup>th</sup> of the diameter of macrophages appeared in BCG-trained, *M. tuberculosis*-  
86 infected macrophage cultures. These ‘corralling cells’, whose nature remains elusive,  
87 apparently concentrated the bacteria into focal points by pushing them in a coordinated fashion,  
88 while limiting their growth. To our knowledge, this phenomenon has not been described  
89 previously.

90

## 91 **Results**

### 92 *Study design*

93 To determine epigenetic changes in the immune cells in TB-exposed individuals, we recruited  
94 subjects enrolled in a routinely performed TB contact tracing at Linköping University Hospital,  
95 Sweden. Age-matched individuals were included as controls (Table 1). The index case was  
96 diagnosed with drug-sensitive pulmonary TB and had completed two out of six months of  
97 standard treatment at the time of sample collection. All included subjects except one (a TB  
98 contact) had been BCG-vaccinated previous to the study (Table 1). Interferon-Gamma Release  
99 Assay (IGRA) status was determined and among the exposed individuals, two were positive

100 (including the index case) and among the controls, one individual (C2) was classified as  
101 ‘borderline’- positive<sup>7</sup> (Table 1). From induced sputum, we used an established protocol for the  
102 isolation of HLA-DR-positive antigen-presenting cells, dominated by macrophages<sup>8</sup> and T  
103 cells (CD3 positive cells) (BioRxiv, 2021, pre-print, accepted for publication in *Epigenetics*),  
104 whereas the PBMC fraction extracted from blood was kept as a mixed population. For the in  
105 vitro experiment with BCG and *M. tuberculosis* exposure, human primary monocytes were  
106 collected from blood samples from healthy blood donors and differentiated into macrophages.  
107 (Fig. 1).

108

#### 109 *DNA methylome data from TB-exposed individuals form a separate cluster*

110 DNA isolation from the studied cell populations was followed by global DNAm analysis using  
111 the Illumina 450K protocol. After curation of the data<sup>9</sup>, the datasets were subjected to  
112 unsupervised hierarchical cluster analysis based on DNA CpG methylation  $\beta$ -values. This  
113 approach accurately clustered the participants into TB-exposed and controls based on the DNA  
114 methylome data derived from both HLA-DR- and CD3-positive cell populations. (Fig. 2a, b).  
115 On the other hand, in the PBMC-derived dataset, the TB index case appeared outside the  
116 clusters and two of the controls clustered with the other exposed individuals, one of them  
117 (“Con\_2”) being the individual identified as borderline-positive in the IGRA test (Fig. 2c).

118

119 Next, we identified the differentially methylated CpG sites (DMCs) and differentially  
120 methylated genes (DMGs) by comparing the TB-exposed and control groups for each cell  
121 population. To filter out the most significantly altered DMGs in the dataset, the stringency  
122 criteria of  $\log_2 > |0.3|$  fold increased or decreased  $\beta$ -values and Benjamini-Hochberg (BH)-  
123 corrected  $p$ -value  $< 0.05$  (HLA-DR),  $< 0.1$  (CD3) and  $< 0.2$  (PBMC) were applied. The results  
124 are depicted as volcano plots, which show that DNA methylomes of TB-exposed most strongly

125 differ in the HLA-DR cells as compared to control subjects, followed by the CD3 population,  
126 whereas PBMC datasets revealed fewer DMGs (Fig. 2d, e, f, Table 2). To highlight the locus  
127 position of the DMGs, chromosome maps were constructed (Suppl. Fig. S1a-c). Using the same  
128 stringency criteria as for the HLA-DR analysis, we tested whether DMGs would emerge when  
129 the datasets were arranged in other possible groups as derived from the demographics (>/<  
130 median age, sex, IGRA status). Neither age nor IGRA status generated any significant DMGs  
131 with these settings, and gender rendered three DMGs (X and Y chromosomes were removed in  
132 the initial filtering prior the analysis) in the HLA-DR positive and in the CD3 positive cells  
133 (Table 2).

134

#### 135 *Functional enrichment analysis reveals common and unique interactomes in the datasets*

136 Using the PANTHER Database, we investigated whether the identified DMGs were enriched  
137 in known pathways (Fig. 3a,b,c). The analysis revealed enrichment in pathways with relevance  
138 for TB infection, including hypoxia-inducible factor (HIF)1- $\alpha$  activation, Vitamin D  
139 metabolism and p38, Wnt, Notch, interleukin, chemokine, and cytokine signaling pathways<sup>10-</sup>  
140 <sup>17</sup>. Common pathways shared between at least two of the cell populations included B cell  
141 activation, glycolysis, angiotensin II signaling, and cholecystikinin signaling. Notably, several  
142 pathways named after their known functions in the nervous system were enriched in the studied  
143 cell populations, including pathways involved in axon guidance and adrenaline, acetylcholine  
144 and glutamate signaling. In the PBMC population but not in the lung cell populations, the  
145 interferon- $\gamma$  signaling pathway was identified among the enriched pathways.

146

#### 147 *Comparisons across cell populations and species reveals the existence of a common DNA* 148 *methylome-based biosignature in mycobacteria-exposed immune cells*

149 Given the fact that the interaction between mycobacteria and eukaryotes is evolutionary ancient,  
150 we predicted that highly conserved pathways exist that are common among the studied cell  
151 populations. Comparing the identified DMGs from the HLA-DR, CD3 and PBMCs in a Venn  
152 analysis, we discovered 185 common DMGs (Fig. 4a). We expanded the Venn analyses to  
153 include data from our previous work on BCG vaccine-induced DMGs that correlated with  
154 enhanced mycobacterial control<sup>4</sup>, as natural exposure to TB and BCG vaccination both  
155 represent *in vivo* encounters between mycobacteria and host immune cells. Even though the  
156 routes of mycobacterial exposure differ profoundly in these settings, a set of 151 DMGs could  
157 be identified as overlapping between our previous BCG study and all cell populations studied  
158 here (Fig. 4b), suggesting that a highly conserved epigenetic response to mycobacterial  
159 challenge exists.

160 In 2018, Hasso-Agopsowicz *et al.* described alterations in DNAm patterns in PBMCs from  
161 BCG-vaccinated individuals, with concomitant enrichment in many immune-related pathways<sup>5</sup>.  
162 In order to compare that study with ours, we performed PANTHER analysis with the 185  
163 common DMGs and matched the identified enriched pathways, revealing that 75% of those  
164 pathways were the same as in the present study (Fig. 5a), further corroborating the relationship  
165 of the altered DNAm patterns induced through TB exposure and BCG-induced changes. In a  
166 recent study by Kaufmann *et al.*, BCG-induced alterations of the epigenome in mice was  
167 correlated with protection against *M. tuberculosis* infection<sup>6</sup>. In order to translate our human  
168 DNA methylome signature to the signature identified in the mouse study, we searched for  
169 pathway overlaps between the two we performed a Gene Ontology (GO) enrichment analysis  
170 (Suppl. Fig. S2a-c). Figure 5b demonstrates that for our PBMC data, the GO terms “biological  
171 processes” overlapped 100% with the mouse study (same cell population) and to 31% and 65%  
172 for HLA-DR- and CD3-positive cells, respectively. In 2014, Saeed *et al* <sup>19</sup> demonstrated the  
173 induction of trained immunity pathways by another immune-training agent,  $\beta$ -glucan. We

174 assessed possible pathway overlap with that study and although there were fewer overlaps as  
175 compared to the BCG-induced pathways described above. Again, the strongest correlation was  
176 found in the PBMC fraction, in this case in the GO terms “cellular components” (Fig. 5c and  
177 Table 1c).

178 To validate how well the 284 CpG sites corresponding to the 185 overlapping DMGs performed  
179 in an unsupervised cluster analysis, we included one additional TB patient and two contacts,  
180 and collected HLA-DR-positive cells from induced sputum, as the DNA methylome data from  
181 this cell type was clearly outperforming the others with respect to accurate separation of the  
182 groups. Fig. 6 shows a *k* means-based dendrogram with a heatmap of the  $\beta$  values of the 284  
183 CpG sites from both previous and new subjects’ DNAm data, revealing a distinct separation of  
184 the subjects in accordance with TB exposure.

185

186 *In vitro* BCG training of macrophages induced DNAm changes corresponding to exposure to  
187 TB

188 To investigate whether the BCG-induced epigenetic changes can be mimicked *in vitro*, we set  
189 up a BCG training experiment with macrophages isolated from donor blood that were trained  
190 with BCG and subsequently infected with the virulent *M. tuberculosis* strain H37Rv (expressing  
191 GFP) and monitored during the course of infection. In a subset of donors, BCG-trained cells  
192 displayed an increased capacity to kill *M. tuberculosis* (Fig. 7a-b) while cell viability was  
193 retained (Fig. 7c-d). DNAm analyses was performed on DNA isolated from these donors’  
194 macrophages 24 hours after BCG training. We identified 7471 DMGs with the stringency  
195 criteria of DNAm difference > 30% and BH corrected *p*-value < 0.01. A PANTHER pathway  
196 analysis based on the identified DMGs showed significant enrichment in the Wnt signaling  
197 pathway, cadherin signaling pathways and angiogenesis, overlapping with the over-represented  
198 pathways in the HLA-DR+ and CD3+ cells from the TB-exposed individuals (Fig. 7e).



199  
200 *BCG training of primary human macrophages induces morphological changes during M.*  
201 *tuberculosis infection*

202 To better understand the mechanism by which BCG enhances the anti-mycobacterial activity  
203 of macrophages, we included N-glycolylated muramyldipeptide (MPD), alongside BCG in the  
204 training experiment with macrophages from ten donors. MDP is a component of the  
205 mycobacterial cell wall and has been described as the minimal component of BCG to induce  
206 trained immunity<sup>20,21</sup> . The infected macrophages were monitored in the IncuCyte® S3 Live  
207 Cell Imaging system. We observed the emergence and expansion of a non-phagocytic cell type  
208 in BCG-trained macrophages from three donors (Fig. 8a-f and supplemental video S1), which  
209 seemed unaffected by high bacterial load. We termed this yet undefined cell type ‘corralling  
210 cells’, based on their apparent coordinated action to relocate and contain bacteria into focal  
211 points. We observed that distinct morphological changes occurred prior the emergence of the  
212 corralling cells and classified this process into 6 distinct stages shown in figure 8a-f. In staining  
213 experiments using Oil Red O, a lipid stain, in paraformaldehyde-fixed cells, we could  
214 demonstrate that the vacuole-like structures were not lipid droplets, excluding the possibility  
215 that this morphological state was reflective of foamy macrophages described previously<sup>22</sup> (Fig.  
216 8g-h). The fixed cells were also stained with fluorescently conjugated antibodies (anti-  $\alpha$ -  
217 smooth muscle actin ( $\alpha$ -SMA), CD68, CD3, CD14, Collagen I and HLA-DR) to identify  
218 potential expression markers on the corralling cells. The HLA-DR antibody positively stained  
219 the macrophages, whereas the corralling cells were negative. (Fig 8i-j). No positive staining  
220 was observed for  $\alpha$ -SMA, CD3, CD14 or collagen I (data not shown). Quantification of the  
221 number of corralling cells revealed that BCG-training cells but not MDP-training significantly  
222 induced the emergence of these cells (Fig. 9a). Finally, we evaluated the outcome for *M.*  
223 *tuberculosis* growth in wells with corralling cells. Figure 9b and supplemental video S2a

224 (corralling) and S2b (non-corralling) show that in wells with corralling cells, the GFP-  
225 fluorescence of *M. tuberculosis* was strongly suppressed.

226

## 227 **Discussion**

228 In this study, we present data suggesting that exposure to TB generates a distinct DNAm  
229 signature in pulmonary immune cells. The signature was found not only in those with active or  
230 latent TB infection, but also in individuals who are exposed but IGRA-negative. The finding  
231 that healthy, TB-exposed individuals also carry the signature opens the possibility that the  
232 epigenetic alterations reflect a host-beneficial reprogramming of the immune mechanisms  
233 rather than being induced by *M. tuberculosis* as a step to evade the immune defense. This notion  
234 is supported by our observation that the DMGs identified in the present study strongly  
235 overlapped with the epigenetic alterations identified in the *in vitro* BCG-trained macrophages,  
236 and the previously reported DNAm changes induced during BCG vaccination, which correlated  
237 with increased anti-mycobacterial capacity of macrophages<sup>4</sup>. In addition, we demonstrate that  
238 the GO data derived from our dataset display a strong overlap with data from a study on  
239 protective BCG vaccination in mice<sup>6</sup>.

240 BCG vaccination has convincingly been shown to induce heterologous immunity protecting  
241 against childhood mortality from other causes than TB<sup>23,24</sup>. Based on our finding that natural  
242 TB exposure and BCG vaccination trigger similar epigenetic changes we propose the  
243 hypothesis that a “beneficial exposure” to TB exists, which protects against other infections  
244 through heterologous immunity. Along the same line, it has been shown that a substantial  
245 fraction of individuals exposed to TB can be defined as ‘early clearers’, since they remain  
246 tuberculin skin test or IGRA negative<sup>25</sup>, suggesting effective eradication of the infection<sup>25</sup>.  
247 Identifying these early clearers and understanding the biology behind their resistance to TB  
248 infection could move the field forward towards novel strategies of TB prevention.

249 In concordance with the fact that macrophages constitute the main niche for mycobacterial  
250 replication, the strongest enrichment of DNAm changes was observed in the HLA-DR-positive  
251 cell population, which is dominated by alveolar macrophages. The pathways identified to be  
252 enriched in the HLA-DR-positive population have been described in the context of trained  
253 immunity, BCG exposure and TB. For example, activation of Hypoxia-Inducible Factor 1  $\alpha$   
254 and glycolysis pathways (P00030 and P00024, respectively) are hallmarks of macrophages that  
255 have undergone the epigenetic changes reflective of trained immunity (reviewed in <sup>26,27</sup>), which  
256 is induced in myeloid cells upon BCG-stimulation<sup>21</sup>. VEGF-release (P00056) by macrophages  
257 has been shown to recruit immune cells during granuloma formation<sup>29</sup>. Further, vitamin D has  
258 been shown to strengthen the anti-mycobacterial activity of macrophages<sup>11,30</sup>, and upregulation  
259 of components of the vitamin D pathway is linked to the production of anti-microbial peptides<sup>12</sup>,  
260 providing a possible effector mechanism for mycobacterial control. Recent literature on  
261 immune regulation through T cell-derived acetylcholine<sup>31,32</sup> attributes relevance to the  
262 acetylcholine receptor pathway identified among the HLA-DR pathways.

263 Although macrophages and lymphocytes are not generally viewed as having many similarities,  
264 we found 34 of the identified pathways to overlap between HLA-DR- and CD3-positive cells.  
265 In data derived from the CD3 and PBMC populations, both of which represent lymphocytes,  
266 overlaps were identified for glycolysis, glutamate receptor and angiotensin II pathways.  
267 Interestingly, a metabolic shift towards increased glycolysis, representative of the Warburg  
268 effect, has been strongly associated with trained immunity<sup>26</sup>. However, the literature is  
269 dominated by the view that this event takes place in trained myeloid cells, while we identified  
270 this circuit in CD3 cells (lymphocytes) and not in the HLA-DR cells (dominated by  
271 macrophages). The glutamate receptor is widely expressed on immune cells and has been  
272 described as having an important regulatory role in T cells, which can also produce and release  
273 glutamate<sup>33</sup>. The role for angiotensin II pathway in TB remains elusive, while Angiotensin II

274 Converting Enzyme 2 is currently in the spotlight due to fact that the SARS-CoV2 virus utilizes  
275 it as a receptor for entry into host cells<sup>35</sup>. In the PBMC population, which over all showed a  
276 weaker epigenetic response, we found the interferon- $\gamma$  signaling pathway, which has a well-  
277 established role in anti-mycobacterial defense (reviewed in <sup>36</sup>), among the reprogramed  
278 pathways.

279 Several studies have ascribed Wnt pathways immunomodulating functions and induction  
280 during *M. tuberculosis* infection (reviewed in <sup>14</sup>) and M1 and M2 macrophages express distinct  
281 patterns of Wnt ligands. Here, in experiments with BCG-trained macrophage cultures, we  
282 observed the emergence of rapidly dividing cells with a size of approximately 1/4<sup>th</sup> of the  
283 diameter of macrophages and negative for HLA-DR staining. A major limitation of the present  
284 study is that the corralling cells' source of origin and mechanism for emergence could not be  
285 identified, but our ongoing studies are designed to characterize these cells. Taken together, we  
286 present data supportive of mycobacteria exposure induced DNAm changes that correlate with  
287 previous findings from studies on BCG vaccination including TB protection and trained  
288 immunity. We propose that the mycobacteria-specific DNAm changes promote the emergence  
289 of corralling cells to restrict mycobacterial growth, although this hypothesis needs further  
290 investigation.

291

## 292 **Methods**

### 293 *Study design and participants*

294 Patients with pulmonary TB, healthy participants with a history of TB-exposure and healthy  
295 controls, with an age ranging from 18 to 53 years, were enrolled at Linköping University  
296 Hospital and Linköping University, respectively. Included subjects (see Table 1 for  
297 demographics) donated peripheral blood and induced sputum samples<sup>37</sup> (BioRxiv, pre-print,  
298 2021, accepted for publication in *Epigenetics*) following oral and written informed consent

299 (ethical approval obtained from the regional ethical review board in Linköping, #2016/237-31).  
300 The study protocol included questionnaires on respiratory and overall health, the evaluation of  
301 IGRA-status and sputum samples for DNA extraction. The subjects' samples and  
302 questionnaires were not linked to any personal information at any stage of the study. For *in*  
303 *vitro* experiments, de-identified buffy coats were purchased from the blood facility at Linköping  
304 University Hospital. The buffy coats were obtained from healthy blood donors, who gave  
305 written consent of research use for the blood products.

306

### 307 *Induced sputum and pulmonary immune cell isolation*

308 Induced sputum is a well-tolerated, non-invasive method to collect cells from the surface of the  
309 bronchial airways after inhalation of a hypertonic saline solution. The procedure of sputum  
310 induction takes approximately 30 minutes and is both cost effective and safe with minimal  
311 clinical risks<sup>38</sup>. Sputum specimens were collected as described by Alexis *et al*<sup>39</sup>, with the  
312 following modifications: premedication with an adrenergic  $\beta$ 2-agonist, salbutamol (Ventoline,  
313 1ml 1mg/ml) was administrated before the inhalation of hypertonic saline, using a nebulizer  
314 (eFlow, PARI). The subsequent steps of sputum processing were adopted from Alexis *et al.*  
315 (2005)<sup>40</sup> and Sikkeland *et al*<sup>8</sup>. The HLA-DR and CD3-positive cells were isolated using  
316 superparamagnetic beads coupled with anti-human CD3 and Pan Mouse IgG antibodies and  
317 HLA-DR/human MHC class II antibodies (Invitrogen Dynabeads, ThermoFisher, cat no 11041  
318 and 14-9956-82, respectively). An initial positive selection was done with CD3 beads followed  
319 by a positive HLA-DR selection. Bead-coating and cell isolation were performed according to  
320 manufacturer's protocol.

321

### 322 *PBMC isolation*

323 PBMCs were isolated from whole blood (TB-exposed and controls) or from leukocyte rich  
324 fractions of blood obtained from healthy volunteers (Linköping University Hospital blood bank,  
325 Linköping). Isolation was performed by the method of density gradient centrifugation using  
326 Lymphoprep (Axis-Shield) and Sepmate-50 tubes (Stemcell Technologies) according to  
327 manufacturer's protocol. IGRA status was determined on the whole-blood samples using  
328 QuantiFERON-TB Gold (Cellestis) following the manufacturer's instructions.

329

### 330 *Cell culture and in vitro BCG training*

331 Following PBMC isolation cells were seeded in cell culture treated flasks in Dulbecco's  
332 Modified Eagle's Medium (DMEM, Invitrogen) with 25 mM hepes, 100 U/ml penicillin and  
333 100 µg/ml streptomycin (PEST, Gibco). Cells were incubated in 37 °C for 2 h before the non-  
334 adherent lymphocytes were washed away using warm Krebs-Ringer Glucose buffer (made in  
335 house). Complete DMEM supplemented with 10% pooled human serum, 2mM L-glutamine,  
336 100 U/ml penicillin and 100 µg/ml streptomycin (all from Gibco) was then added to the cells  
337 along with immune training agents, or medium only as negative control for 24h. For the DNA  
338 methylation analysis and data presented in figure 7 a-d we used 10 µg/ml of BCG (freeze dried  
339 *M. bovis bacillus Calmette-Guérin* Danish Strain). For the 10 donor experiment including MDP  
340 and data presented in figures 8 and 9 we instead used 3.33 µg/ml BCG or 3.33 µg/ml N-  
341 glycolylated muramyl dipeptide (MDP) (Invivogen). Training agents were washed off and the  
342 cells were incubated for 6-7 days in complete medium with media change every 2-3 days. The  
343 cells were washed with PBS followed by trypsinization and reseeded of 5000 cells/ well in a  
344 384-well plate (Corning Falcon) for infection experiments. DNAm analysis DNA was isolated  
345 at day 6 after training with BCG.

346

347 *M. tuberculosis* culture and infection of macrophages

348 The laboratory *M. tuberculosis* strain, H37Rv, carrying the green fluorescent protein (GFP)-  
349 encoding pFPV2 plasmid (*M. tuberculosis*-GFP) was grown in Middlebrook 7H9 broth  
350 supplemented with albumin-dextrose-catalase (ADC, Becton-Dickinson), 0.05% Tween-80,  
351 and the selection antibiotic Kanamycin at 20 $\mu$ g/ml for two to three weeks at 37°C. The bacteria  
352 were then re-seeded in fresh broth for an additional 7 days to reach early log phase for use in  
353 experiments. For infection, the harvested bacteria were washed, resuspended in antibiotic-free  
354 complete DMEM and filtered through a Milliplex-®SV 5.0 $\mu$ m syringe filter (Merck) to remove  
355 bacterial clumps. Macrophages were infected with *M. tuberculosis* at a multiplicity of infection  
356 (MOI) 0.5 and the cells imaged using an IncuCyte® S3 (IncuCyte® Live-Cell 120 Analysis  
357 System, Sartorius). The relative fluorescence signal (RFU) of bacteria was measured every 4  
358 hours (20x, 4 images/well) until day 7 post-infection, analyzed using IncuCyte® S3 software  
359 and expressed as total integrated intensity of green objects (GCU $\times\mu$ m<sup>2</sup>/image).

360

361 *Identification of morphological changes and quantification of corraling*

362 Manual identification of morphological stages was performed by importing 8-bit grayscale  
363 images from the IncuCyte® S3 software to ImageJ<sup>41</sup> using the Fiji package<sup>42</sup>. All images were  
364 processed to enhance contrast by 2% for ease of viewing. The number of coralling cells was  
365 manually estimated in images displayed in the IncuCyte® S3 software. Bacterial area was  
366 determined using the basic analyzer tool in the IncuCyte® S3 software.

367

368 *Immunohistochemistry for characterization of corraling cells*

369 The 384-well culturing plates that were used to monitor the cells in the IncuCyte® were fixed  
370 on day 10-11 from the infection. The plates were washed 2x in PBS before adding 4%  
371 paraformaldehyde in PBS for 30 minutes. The plate was washed again x2 in PBS and stored in

372 PBS in 4 degrees until use. For the immunohistochemistry, the wells stained with intracellular  
373 markers ( $\alpha$ -SMA) were permeabilized with 50 ul PBS (made in house) containing 1% bovine  
374 serum albumin (BSA) (Sigma-Aldrich, St. Luis, Missouri, U.S) and 0.2% Triton X-100 (Sigma  
375 Aldrich)/well for 10 min. No permeabilization was used for the staining of extracellular markers  
376 (CD3, CD14, CD68, HLA-DR, Collagen  $\alpha$ 2 Type I). The wells were washed 3 times with PBS  
377 and then 50 ul blocking buffer containing 1% BSA in PBS was added and the plate was  
378 incubated at RT for 1 h. The antibodies were diluted in PBS 1% BSA and added in a volume  
379 of 10 ul/well. The antibodies used were CD68 Alexa Fluor 647 diluted 1:25 (Cat no: sc-17832,  
380 Santa Cruz Biotechnology, Dallas, Texas, U.S), CD68 Alexa Fluor 647 diluted 1:20 (Cat no:  
381 562111, BD biosciences, Franklin Lakes, New Jersey, U.S),  $\alpha$ -SMA Alexa Fluor 488 diluted  
382 1:50 (Cat no: sc-32251, Santa Cruz Biotechnology), CD3 FITC diluted 1:50 (Cat no: 349201,  
383 BD Biosciences), CD3 FITC diluted 1:50 (Cat no: 300306, Biolegend, San Diego, California,  
384 U.S), HLA-DR PE diluted 1:20 (Cat no: 327007, Biolegend), CD14 FITC diluted 1:20 (Cat no:  
385 345784, BD biosciences), Collagen  $\alpha$ 2 Type I Alexa Fluor 647 diluted 1:50 (Cat no: 393573,  
386 Santa Cruz Biotechnology). For isotype controls we used normal mouse isotype control IgG<sub>1</sub>  
387 Alexa Fluor 647 (Cat no: sc-24636, Santa Cruz Biotechnology) diluted 1:50, normal mouse  
388 isotype control IgG<sub>2a</sub> Alexa Fluor 488 (Cat no: sc-3891, Santa Cruz Biotechnology) diluted  
389 1:50) and normal mouse isotype control IgG<sub>2b</sub> FITC (Cat no: 0090480, BD Biosciences). The  
390 plate was incubated for 1 h in RT. The pate was 3x in PBS and 20 ul Dako Mounting Medium  
391 (Agilent, Santa Clara, California, U.S) was added. The plate was read in the IncuCyte<sup>®</sup> S3 Live  
392 Cell Imaging system at x20.

393

#### 394 *DNAm sequencing and data analysis*

395 DNA from PBMCs, HLA-DR-positive, CD3-positive cells, and the cultured human primary  
396 macrophages was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany)



397 according to the manufacturer's instructions. Genome-wide DNAm analysis was performed  
398 using the HumanMethylation450K BeadChip (Illumina, USA) array (for the HLA-DR, CD3,  
399 PBMC samples) and reduced representation bisulfite sequencing (Diagenode's RRBS) read in  
400 Illumina's HiSeq 2000 (for the cultured human primary macrophages) at the Bioinformatics  
401 and Expression Analysis (BEA) Core Facility at Karolinska Institute, Stockholm. The  
402 methylation profiles from the HumanMethylation450K BeadChip analysis for each cell type  
403 were analyzed from the raw IDAT files in R (v4.0.2) using the *minfi* (v1.36.0) with subset-  
404 quantile within array (SWAN) normalization<sup>43,44</sup> and *ChAMP* (v2.19.3) with beta-mixture  
405 quantile normalization (BMIQ) packages<sup>45,46</sup>. The type I and type II probes were normalized  
406 using the quantile normalization method. Using the default setup of the *ChAMP* package,  
407 following probes were filtered out: i) probes below the detection *p*-value ( $>0.01$ ), ii) non-CpG  
408 probes, iii) multi-hit probes, and iv) all probes of X and Y chromosomes. Cell type  
409 heterogeneity was corrected for the PBMC cell types using the Houseman algorithm<sup>47</sup> and batch  
410 effects were fixed using *ComBat* from the *SVA* package (v3.38.0). Differential methylation  
411 analysis was performed with the linear modeling (lmFit) using the *limma* package<sup>48</sup> (v3.46.0)  
412 in a contrast matrix of the TB-exposed and TB-non-exposed (Control) individuals. All  
413 Differentially methylated CpGs (DMCs) were considered significant at the Bonferroni-  
414 Hochberg (BH) corrected *p*-value  $< 0.05$  (for HLA-DR cell types),  $<0.1$  (for CD3 cell types)  
415 and  $<0.2$  (for PBMC cell types). The DNA from the human primary macrophages was  
416 sequenced using the Diagenode's RRBS due to a lower DNA yield. The sequenced reads were  
417 quality checked using the FastQC<sup>49</sup> (v0.11.9). The sequences were trimmed to remove  
418 artificially filled-in cytosines at the 3' end using the TrimGalore (v0.6.5)(  
419 <https://github.com/FelixKrueger/TrimGalore>) with a phred score cutoff of 20 and quality  
420 checked again after trimming. The trimmed sequences were aligned with the human reference  
421 genome (hg38.13) using Bowtie2<sup>50</sup> and removed the duplicates using the Bismark (v0.22.3)<sup>51</sup>.

422 The methylation extractor from Bismark was used to extract the CpG methylation data from  
423 the sequences. The SAMtools (v1.7) package<sup>52</sup> was used to sort the binary alignment files  
424 (BAM) files on CpG-site chromosomal location and converted to sequence alignment map  
425 (SAM) files. The methylated and unmethylated CpG counts were extracted and combined using  
426 the DMRfinder<sup>53</sup> (v0.3) package in R (v4.0.2). The CpG-sites located in the X and Y  
427 chromosome as well as CpG-sites from mitochondrial DNA were filtered out. For differential  
428 methylation analysis the *methylKit*<sup>54</sup> (v1.18.0) package was used. CpG-sites with a read  
429 coverage > 10 with both methylated and unmethylated reads were removed from the analysis.  
430 The function “calculateDiffMeth” from methylKit package using logistic regression was used  
431 as statistical test with “before” and “after” BCG-training as treatment used to identify  
432 differentially methylated CpG-sites DMCs. The DMCs were annotated to the official gene  
433 symbol using *org.Hs.eg.db* (v3.12) and AnnotationDbi (v1.52) packages using the human  
434 genome version hg38. DMGs were defined as sites with a methylation difference of 30%  
435 between the conditions and an BH corrected *p*-value of <0.01.

436

#### 437 *Unsupervised cluster analysis*

438 Hierarchical clustering of the all TB-exposed and control individuals was performed with the  
439 normalized  $\beta$ -values obtained after the data filtration in each cell type individually. The  
440 distance was calculated using the Euclidean distance matrix. The *dendextend*<sup>55</sup> (v1.14.0) and  
441 *ape*<sup>56</sup> (v5.4-1) packages in R were used to construct the horizontal hierarchical plots from the  
442 three different cell populations using the *hclust* and *dendrogram* functions.

443

#### 444 *Structural annotations*

445 The *EnhancedVolcano* package<sup>57</sup> (v1.8.0) was used to generate the individual volcano plots  
446 from all cell populations. The *ChromoMap* package<sup>58</sup> (v0.3) was used to annotate and

447 visualize the genome-wide chromosomal distribution of the DMGs. The interactive plots were  
448 generated using the *plotly* (v4.9.3) package.

449 The heatmaps were generated from the filtered DMGs with their respective CpGs for each  
450 cell type using the *ComplexHeatmap* (v2.6.2) package<sup>59</sup>. The clustering dendrogram in  
451 heatmaps were plotted using the Euclidean distance matrix.

452

#### 453 *Pathway and functional enrichment analyses*

454 We used the PANTHER database (PantherDB v15, 16)<sup>60</sup> to identify the enriched pathways  
455 related to our identified DMGs. In addition, to assess functional enrichment, we used the  
456 *ReactomePA* (v1.34.0) package<sup>61</sup> with 1000 permutations and the BH-corrected *p*-values.

457 Within the package, GO and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used  
458 and using *clusterProfiler*<sup>62</sup> (v3.18.1), we performed KEGG pathway<sup>63</sup> enrichment analysis  
459 (data not shown). To enhance the visualization and better understanding of the enrichment  
460 result, *GOpilot*<sup>64</sup> (v1.0.2), another package was used. The pathway enrichment was also  
461 calculated using the topology-based ontology methods using *RontoTools*<sup>65</sup> (v2.18.0), *SPIA*<sup>67</sup>  
462 (v2.42.0) and *pathview*<sup>68</sup> (v1.30.1) was used to visualize the related pathways with the KEGG  
463 pathway maps (data not shown).

464

#### 465 *Venn and overlap analyses*

466 Venn analyses were performed to detect the DMGs overlapping between cell populations and  
467 between studies. We constructed the Venn diagrams by using *matplotlib-venn* package  
468 (<https://github.com/konstantint/matplotlib-venn>) using in-house python script. The overlap  
469 analyses were calculated and plotted using the *go.Sunburst* function from *plotly* using an in-  
470 house python script.

471

472 *Statistical analyses*

473 All differences with a  $p$ -value  $< 0.05$  were considered significant if not otherwise stated. We  
474 calculated family-wise error rate (FWER) using the BH correction method. All analyses were  
475 performed in R (v4.0.2) with the mentioned packages.

476

477 **Acknowledgements**

478 This study was funded through generous grants from Forskningsrådet Sydöstra Sverige  
479 (FORSS-932096), the Swedish Research Council (2015-02593 and 2018-02961) and the  
480 Swedish Heart Lung Foundation (20150709 and 20180613). J.D is a postdoctoral fellow  
481 supported through the Medical Infection and Inflammation Center (MIIC) at Linköping  
482 University. We direct our gratitude to the staff at Linköping University Hospital and the  
483 Vrinnevi Hospital in Norrköping for assistance in sample collection and all the subjects for  
484 donating samples. The DNA methylome data were generated at the Bioinformatics and  
485 Expression Analysis Core Facility at the Department of Biosciences and Nutrition, which is  
486 supported by the Board of Research at the Karolinska Institute, Stockholm. The computations  
487 were enabled by resources provided by the Swedish National Infrastructure for Computing  
488 (SNIC) at Linköping University campus partially funded by the Swedish Research Council  
489 through grant agreement no. 2018-05973.

490

491 **Author contributions**

492 M.L., N.I., J.P. and C.B. designed the study, I.P., N.I., C.B., L.K., B.A. and E.K.D performed  
493 the laboratory work and the related analyses, J.D. and M.L. designed and performed the  
494 bioinformatic analyses of the data, J.D. and L.K wrote the scripts for analysis and created  
495 figures. N.I., I.P., J.D., L.K., C.B., E.K.D. and M.L wrote the manuscript. J.D and M.L are co-  
496 authors of a patent application “Biomarker for detection of mycobacterial infection and  
497 exposure” filed on February 2<sup>nd</sup> with the Swedish Patent Registry (#100692).

## References

1. Fitchett, J. R., MacPherson, P. & Corbett, E. L. Implementing the end TB strategy and the intersection with the sustainable development goals, 2016-2030. *Transactions of the Royal Society of Tropical Medicine and Hygiene* (2015) doi:10.1093/trstmh/trw010.
2. Donald, P. R. *et al.* Droplets, dust and Guinea pigs: An historical review of tuberculosis transmission research, 1878-1940. *Int. J. Tuberc. Lung Dis.* (2018) doi:10.5588/ijtld.18.0173.
3. Davis, J. M. & Ramakrishnan, L. The Role of the Granuloma in Expansion and Dissemination of Early Tuberculous Infection. *Cell* (2009) doi:10.1016/j.cell.2008.11.014.
4. Verma, D. *et al.* Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects. *Sci. Rep.* **7**, (2017).
5. Hasso-Agopsowicz, M., Scriba, T. J., Hanekom, W. A., Dockrell, H. M. & Smith, S. G. Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination. *Sci. Rep.* (2018) doi:10.1038/s41598-018-31537-9.
6. Kaufmann, E. *et al.* BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. *Cell* (2018) doi:10.1016/j.cell.2017.12.031.
7. Jonsson, J. *et al.* A borderline range for Quantiferon Gold In-Tube results. *PLoS One* (2017) doi:10.1371/journal.pone.0187313.
8. Sikkeland, L. I. B., Kongerud, J., Stangeland, A. M., Haug, T. & Alexis, N. E. Macrophage enrichment from induced sputum [3]. *Thorax* (2007) doi:10.1136/thx.2006.073544.
9. Das, J., Verma, D., Gustafsson, M. & Lerm, M. Identification of DNA methylation patterns predisposing for an efficient response to BCG vaccination in healthy BCG-naïve subjects. *Epigenetics* (2019) doi:10.1080/15592294.2019.1603963.
10. Ogryzko, N. V. *et al.* Hif-1 $\alpha$ -Induced Expression of Il-1 $\beta$  Protects against Mycobacterial Infection in Zebrafish. *J. Immunol.* **202**, (2019).
11. Eklund, D. *et al.* Vitamin D enhances IL-1 $\beta$  secretion and restricts growth of Mycobacterium tuberculosis in macrophages from TB patients. *Int. J. Mycobacteriology* (2013) doi:10.1016/j.ijmyco.2012.11.001.
12. Liu, P. T. *et al.* Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science (80-. )*. **311**, 1770–1773 (2006).
13. Hölscher, C. *et al.* Chemical p38 MAP kinase inhibition constrains tissue inflammation and improves antibiotic activity in Mycobacterium tuberculosis-infected mice. *Sci.*

- Rep.* (2020) doi:10.1038/s41598-020-70184-x.
14. Brandenburg, J. & Reiling, N. The Wnt blows: On the functional role of Wnt signaling in mycobacterium tuberculosis infection and beyond. *Frontiers in Immunology* (2016) doi:10.3389/fimmu.2016.00635.
  15. Castro, R. C. *et al.* NOTCH1 and DLL4 are involved in the human tuberculosis progression and immune response activation. *Tuberculosis* (2020) doi:10.1016/j.tube.2020.101980.
  16. Eklund, D. *et al.* Human gene variants linked to enhanced NLRP3 activity limit intramacrophage growth of mycobacterium tuberculosis. in *Journal of Infectious Diseases* (2014). doi:10.1093/infdis/jit572.
  17. Raffetseder, J. *et al.* Replication rates of mycobacterium tuberculosis in human macrophages do not correlate with mycobacterial antibiotic susceptibility. *PLoS One* (2014) doi:10.1371/journal.pone.0112426.
  18. Kaufmann, E. *et al.* BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis. *Cell* **172**, 176-190.e19 (2018).
  19. Saeed, S. *et al.* Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. *Science* (80-. ). (2014) doi:10.1126/science.1251086.
  20. Mourits, V. P. *et al.* BCG-Induced Trained Immunity in Healthy Individuals: The Effect of Plasma Muramyl Dipeptide Concentrations. *J. Immunol. Res.* (2020) doi:10.1155/2020/5812743.
  21. Kleinnijenhuis, J. *et al.* Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc. Natl. Acad. Sci. U. S. A.* (2012) doi:10.1073/pnas.1202870109.
  22. Russell, D. G., Cardona, P. J., Kim, M. J., Allain, S. & Altare, F. Foamy macrophages and the progression of the human tuberculosis granuloma. *Nature Immunology* (2009) doi:10.1038/ni.1781.
  23. Benn, C. S., Fisker, A. B., Whittle, H. C. & Aaby, P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. *EBioMedicine* (2016) doi:10.1016/j.ebiom.2016.07.016.
  24. Thysen, S. M. *et al.* Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: A prospective cohort study. *BMJ Open* (2020) doi:10.1136/bmjopen-2019-035595.
  25. Verrall, A. J. *et al.* Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia. *J. Infect. Dis.* (2019) doi:10.1093/infdis/jiz168.
  26. Arts, R. J. W., Joosten, L. A. B. & Netea, M. G. Immunometabolic circuits in trained immunity. *Seminars in Immunology* (2016) doi:10.1016/j.smim.2016.09.002.

27. Kumar, R. *et al.* Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. *Frontiers in Molecular Biosciences* (2019) doi:10.3389/fmolb.2019.00105.
28. Kleinnijenhuis, J. *et al.* Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. *Proc. Natl. Acad. Sci.* **109**, 17537–17542 (2012).
29. Harding, J. S. *et al.* VEGF-A from Granuloma Macrophages Regulates Granulomatous Inflammation by a Non-angiogenic Pathway during Mycobacterial Infection. *Cell Rep.* (2019) doi:10.1016/j.celrep.2019.04.072.
30. Rao Muvva, J., Parasa, V. R., Lerm, M., Svensson, M. & Brighenti, S. Polarization of Human Monocyte-Derived Cells With Vitamin D Promotes Control of Mycobacterium tuberculosis Infection. *Front. Immunol.* (2020) doi:10.3389/fimmu.2019.03157.
31. Cox, M. A. *et al.* Beyond neurotransmission: acetylcholine in immunity and inflammation. *Journal of Internal Medicine* (2020) doi:10.1111/joim.13006.
32. Cox, M. A. *et al.* Choline acetyltransferase-expressing T cells are required to control chronic viral infection. *Science* (80-. ). (2019) doi:10.1126/science.aau9072.
33. Ganor, Y. & Levite, M. The neurotransmitter glutamate and human T cells: Glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. *J. Neural Transm.* (2014) doi:10.1007/s00702-014-1167-5.
34. Ganor, Y. & Levite, M. The neurotransmitter glutamate and human T cells: Glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. *J. Neural Transm.* **121**, 983–1006 (2014).
35. Kuhn, J. H., Li, W., Radoshitzky, S. R., Choe, H. & Farzan, M. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies. *Antiviral Therapy* (2007).
36. Lake, M. A., Ambrose, L. R., Lipman, M. C. I. & Lowe, D. M. 'Why me, why now?' Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. *BMC Med.* (2016) doi:10.1186/s12916-016-0606-6.
37. Das, J., Idh, N., Sikkeland, L. I. B., Paues, J. & Lerm, M. DNA methylome-based validation of induced sputum as an effective protocol to study lung immunity: construction of a classifier of pulmonary cell types. *bioRxiv* (2021) doi:10.1101/2021.03.12.435086.
38. Ugarte-Gil, C., Elkington, P. T., Gotuzzo, E., Friedland, J. S. & Moore, D. A. J. Induced sputum is safe and well-tolerated for TB diagnosis in a resource-poor primary healthcare setting. *American Journal of Tropical Medicine and Hygiene* (2015)



- doi:10.4269/ajtmh.14-0583.
39. Alexis, N., Soukup, J., Ghio, A. & Becker, S. Sputum phagocytes from healthy individuals are functional and activated: A flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood. *Clin. Immunol.* (2000) doi:10.1006/clim.2000.4911.
  40. Alexis, N. E. *et al.* In vivo particle uptake by airway macrophages in healthy volunteers. *Am. J. Respir. Cell Mol. Biol.* (2006) doi:10.1165/rcmb.2005-0373OC.
  41. Rueden, C. T. *et al.* ImageJ2: ImageJ for the next generation of scientific image data. *BMC Bioinformatics* (2017) doi:10.1186/s12859-017-1934-z.
  42. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. *Nature Methods* (2012) doi:10.1038/nmeth.2019.
  43. Maksimovic, J., Gordon, L. & Oshlack, A. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. *Genome Biol.* (2012) doi:10.1186/gb-2012-13-6-r44.
  44. Aryee, M. J. *et al.* Minfi: A flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. *Bioinformatics* (2014) doi:10.1093/bioinformatics/btu049.
  45. Teschendorff, A. E. *et al.* A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. *Bioinformatics* (2013) doi:10.1093/bioinformatics/bts680.
  46. Morris, T. J. *et al.* ChAMP: 450k Chip Analysis Methylation Pipeline. *Bioinformatics* **30**, 428–430 (2014).
  47. Houseman, E. A., Molitor, J. & Marsit, C. J. Reference-free cell mixture adjustments in analysis of DNA methylation data. *Bioinformatics* (2014) doi:10.1093/bioinformatics/btu029.
  48. Ritchie, M. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies | Nucleic Acids Research | Oxford Academic. *limma powers Differ. Expr. Anal. RNA-sequencing microarray Stud.* (2015).
  49. Andrews S. FastQC A Quality control tool for high throughput sequence data. *Babraham Bioinfo* (2018).
  50. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* (2012) doi:10.1038/nmeth.1923.
  51. Krueger, F. & Andrews, S. R. Bismark: A flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics* (2011) doi:10.1093/bioinformatics/btr167.
  52. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* (2009) doi:10.1093/bioinformatics/btp352.

53. Gaspar, J. M. & Hart, R. P. DMRfinder: Efficiently identifying differentially methylated regions from MethylC-seq data. *BMC Bioinformatics* (2017) doi:10.1186/s12859-017-1909-0.
54. Akalin, A. *et al.* MethylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. *Genome Biol.* (2012) doi:10.1186/gb-2012-13-10-R87.
55. Galili, T. dendextend: An R package for visualizing, adjusting and comparing trees of hierarchical clustering. *Bioinformatics* (2015) doi:10.1093/bioinformatics/btv428.
56. Paradis, E. & Schliep, K. Ape 5.0: An environment for modern phylogenetics and evolutionary analyses in R. *Bioinformatics* (2019) doi:10.1093/bioinformatics/bty633.
57. Blighe, K, S Rana, and M. L. EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling. (2018).
58. Anand, L. & Rodriguez Lopez, C. M. ChromoMap: An R package for Interactive Visualization and Annotation of Chromosomes. *bioRxiv* (2019) doi:10.1101/605600.
59. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* (2016) doi:10.1093/bioinformatics/btw313.
60. Thomas, P. D. *et al.* PANTHER: A library of protein families and subfamilies indexed by function. *Genome Res.* **13**, 2129–2141 (2003).
61. Yu, G. & He, Q. Y. ReactomePA: An R/Bioconductor package for reactome pathway analysis and visualization. *Mol. Biosyst.* (2016) doi:10.1039/c5mb00663e.
62. Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. *Omi. A J. Integr. Biol.* (2012) doi:10.1089/omi.2011.0118.
63. Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* (2000) doi:10.1093/nar/28.1.27.
64. Walter, W., Sánchez-Cabo, F. & Ricote, M. GOplot: An R package for visually combining expression data with functional analysis. *Bioinformatics* (2015) doi:10.1093/bioinformatics/btv300.
65. Luo, W., Friedman, M. S., Shedden, K., Hankenson, K. D. & Woolf, P. J. GAGE: Generally applicable gene set enrichment for pathway analysis. *BMC Bioinformatics* (2009) doi:10.1186/1471-2105-10-161.
66. Voichita, C., Ansari, S. & Draghici, S. *ROntoTools: The R Onto-Tools suite.* <https://bioconductor.riken.jp/packages/3.10/bioc/vignettes/ROntoTools/inst/doc/rontotools.pdf> (2019).
67. Tarca, A. L. *et al.* A novel signaling pathway impact analysis. *Bioinformatics* (2009)

doi:10.1093/bioinformatics/btn577.

68. Luo, W. & Brouwer, C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. *Bioinformatics* **29**, 1830–1831 (2013).

## Tables

Characteristics	TB-exposed (n = 4)	Controls (n = 6)
Mean age (year) <sup>†</sup>	36±12	27±6
Mean height (cm) <sup>†</sup>	173±4	176±7
Mean weight (kg) <sup>†</sup>	69±8	77±16
Mean Body Mass Index (BMI) <sup>†</sup>	23±3	24±5
Sex (male/female)	1/3	4/2
Smoking (current/previous/never)	0/1/3	0/0/6
BCG (yes/no)	3/1	6/0
IGRA-positive/IGRA-negative	2/2	1*/5

Table 1: Demographic data of the participants.

<sup>†</sup>The standard deviation of the mean values is added to the age, height, weight and BMI.

\* Borderline-positive.

Characteristics		Cell type	DMGs	Gene name	p-value
<b>TB Exposure</b>	exposed vs. controls	HLA-DR	9,786	(not shown)	0.05
		CD3	5,045	(not shown)	
		PBMC	496	(not shown)	
<b>Age</b>	< 30 vs. ≥ 30	HLA-DR	0		0.05
		CD3	0		
		PBMC	0		
<b>Gender</b>	male vs. female	HLA-DR	3	GALNTL5; MIR3201; OPN3	
		CD3	3	COL9A1; ACTG1; REAT1E	
		PBMC	0		
<b>IGRA</b>	positive vs. negative	HLA-DR	0		
		CD3	0		
		PBMC	0		
<b>BMI</b>	> 25 vs ≤ 25	HLA-DR	0		
		CD3	0		
		PBMC	0		

Table 2: Differentially methylated genes (DMGs) identified through comparison of different study participant characteristics (TB-exposure, age, gender, IGRA status and BMI) in the three different cell populations, CD3+, HLA-DR+ and PBMC. DMGs were only identified when comparing the characteristic TB-exposure and gender.

<b>Characteristics</b>	<b>TB patients (n = 2)</b>	<b>TB-exposed (n = 2)</b>
Mean age (year) <sup>†</sup>	19.5±1.5 <sup>†</sup>	35.5±17.5
Mean height (cm) <sup>†</sup>	176±7	171±3
Mean weight (kg) <sup>†</sup>	62.5±6.5	80±10
Mean Body Mass Index (BMI) <sup>†</sup>	19.9±0.6	27.3±2.5
Sex (male/female)	2/0	1/1
Smoking (current/previous/never)	2/0/0	1/0/1
BCG (yes/no)	0/2	2/0

Table 3: Demographic data of the participants in the second recruitment (“test dataset”)

<sup>†</sup>The standard deviation of the mean values of age, height, weight, and BMI.

## Figures & figure legends




Figure 1. Schematic overview of the project workflow. Sputum and blood were isolated from TB-exposed individuals and controls and the DNA methylomes were analyzed for the different cell types. Macrophages were isolated from healthy blood donors and exposed to the Bacillus Calmette–Guérin (BCG) vaccine *in vitro*. The BCG-exposed macrophages were subjected to DNA methylome analysis and in parallel, infected with *M. tuberculosis* and monitored in a live cell imaging system.




Figure 2. DNA methylome analyses of immune cells from TB-exposed individuals. Dendrograms of the unsupervised hierarchical clustering of the DNAm  $\beta$ -values of from **a.** HLA-DR, **b.** CD3 and **c.** PBMCs. “Con”: green=controls, “Exp”: purple=TB-exposed, red=TB index case. The scale defines the clustering Euclidean distance.






Figure 2. DNA methylome analyses of immune cells from TB-exposed individuals. Volcano plots of DMGs from **d**. HLA-DR, **e**. CD3 and **f**. PBMCs. Red dots represent DMGs above cut-offs ( $\pm 0.3$  Log<sub>2</sub> fold change and BH-corrected  $p$ -value  $< 0.05$ ,  $< 0.1$  or  $0.2$  as indicated).




Figure 3. PANTHER pathway analysis of the identified DMGs with the cut-offs for the different cell populations given in Figure 2. Dot plots show the gene ratio, gene counts and FDR-corrected  $p$ -value for **a.** HLA-DR (top 20 pathways), **b.** CD3 (total 17 pathways)




Figure 3. PANTHER pathway analysis, continued. **c.** PBMC (top 20 pathways).




Figure 4: Venn analyses comparing DMGs, pathways and GO terms between different datasets.

**a.** Overlapping DMGs derived from the HLA-DR (orange), CD3 (green) and PBMC (red) DNA methylomes. **b.** Overlapping DMGs from this study and from our previous work on BCG induced DMGs (light green).




Figure 5. Pathway overlap with other studies' results. **a.** Venn diagram describing the number of Panther pathways overlapping between the ones derived from the 185 common DMGs in this study (dark green) and Hasso-Agopsowicz *et al* (human BCG vaccine study, light green) **a.** Sunburst Plot describing the overlap of enriched GO biological processes emerging from a comparison between the GO data derived from the 185 common DMGs (Figure 4a) and Kaufmann *et al* (BCG study performed in mouse PBMCs).




Figure 5. Pathway overlap with other studies' results, continued. **c.** Sunburst Plot describing the overlap of enriched GO biological processes emerging from a comparison between the GO data derived from the 185 common DMGs and Saeed *et al* (study on trained immunity induced by  $\beta$ -glucan).




Figure 6. Heatmap of the HLA-DR-derived  $\beta$  values of the signature's 284 CpG sites of the 6 initial subjects (Exp\_1-4 and Con\_1-6) and the three additional exposed subjects (Exp\_6-8). Purple=exposed, red=TB index case, green=controls.




Figure 7. Macrophages were BCG-trained (purple) or left untreated (orange) before infection with *M. tuberculosis* (H37rv-GFP) or DNAm analysis. **a-b**. Total bacterial area ( $\mu\text{m}^2/\text{image}$ ) measured by green fluorescence over time. **c-d**. Cumulative cell death measured by the red fluorescent DRAQ7 DNA stain marking the nuclei of non-viable cells. **a-d** shows data from one donor separately with the median of two replicates per timepoint. **e**. PANTHER pathway analysis of the identified DMGs from DNA methylation analysis in the human primary



macrophages exposed to BCG compared to controls. Dot plots show the gene ratio, gene counts and FDR-corrected  $p$ -value for 3 significantly over-represented pathways.




Figure 8. Morphological staging of the emergence of corralling cells (images representative of 3 donors with 4-6 technical replicates). **a.** Macrophages with red fluorescently labelled nuclei using NuLight and *M. tuberculosis* (H37rv-GFP) fluorescent in green by GFP-expression, arrow showing intracellular *M. tuberculosis*. **b.** Stretching; Macrophages form extensions (100-300  $\mu\text{m}$  long) during the first 24 hours **c.** Vacuolization; non-stretching macrophages become vacuolized (initially  $<1\mu\text{m}$  in diameter, increasing to 15  $\mu\text{m}$  within 24-36 hours). **d.** Emergence; the presence of corralling cells is obvious at day 3 after which their numbers increase **e.** Corraling; corraling cells engage in pushing the bacteria into focal areas. **f.** Containment; *M. tuberculosis* bacteria are contained in the focal areas. **g-h.** Paraformaldehyde-fixed cells stained with Oil red O (red). Arrows indicate vacuolization. **i-j** Paraformaldehyde-fixed cells stained with fluorescently labelled anti-HLA-DR (red). Arrows indicate corralling cells.




Figure 9. **a.** Quantification of corraling cells in *M. tuberculosis*-infected cultures with BCG- and MDP-trained macrophages. Cells with a size of 10-20 μm length were manually counted in 4-6 technical replicates from three donors. Statistical analysis was done with the Kruskal-Wallis test with Dunn's multiple comparisons (*p*-value as indicated). **b.** *M. tuberculosis* (strain H37rv-GFP) fluorescence area (μm<sup>2</sup>/well) measured in 12-well plates in the IncuCyte® S3 analysis tool for 2 donors with corraling cells (pink) and 2 donors without corraling cells (blue), error bars show SEM.